DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/6mtzp6/recurrent) has announced the addition of the "Recurrent Malignant Glioma Global Clinical Trials Review, H1, 2014" report to their offering.
Recurrent Malignant Glioma Global Clinical Trials Review, H1, 2014" provides data on the Recurrent Malignant Glioma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Recurrent Malignant Glioma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Recurrent Malignant Glioma.
Espy the commercial landscape of the major Universities / Institutes / Hospitals & Companies
- Insys Therapeutics, Inc.
- Merck & Co., Inc.
- Eisai Co., Ltd.
- TransMolecular, Inc.
- Eli Lilly and Company
- to-BBB technologies BV
- Tactical Therapeutics, Inc
- Shandong Lanjin Pharmaceuticals Co. Ltd
- Direct Therapeutics, Inc.
- Amgen Inc.
- National Cancer Institute
- Duke University
- Memorial Sloan Kettering Cancer Center
- North American Brain Tumor Consortium
- The University of Texas M. D. Anderson Cancer Center
- Northwestern University
- UCLA's Jonsson Comprehensive Cancer Center
- Sidney Kimmel Comprehensive Cancer Center
- University of Colorado
- Wake Forest University
For more information visit http://www.researchandmarkets.com/research/6mtzp6/recurrent
